Yestar Healthcare Holdings Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Yestar Healthcare Holdings.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth	38.8%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Yestar Healthcare Holdings' (HKG:2393) Attractive Earnings Are Not All Good News For Shareholders

Sep 19

Yestar Healthcare Holdings (HKG:2393) Seems To Be Using A Lot Of Debt

Dec 13

These Return Metrics Don't Make Yestar Healthcare Holdings (HKG:2393) Look Too Strong

Oct 18

Is Yestar Healthcare Holdings (HKG:2393) Using Too Much Debt?

Sep 05

One Yestar Healthcare Holdings Company Limited (HKG:2393) Analyst Has Been Cutting Their Forecasts

Sep 05

Returns On Capital At Yestar Healthcare Holdings (HKG:2393) Have Hit The Brakes

Jun 10

These 4 Measures Indicate That Yestar Healthcare Holdings (HKG:2393) Is Using Debt Extensively

Apr 18

What Kind Of Investors Own Most Of Yestar Healthcare Holdings Company Limited (HKG:2393)?

Mar 15

The Returns At Yestar Healthcare Holdings (HKG:2393) Provide Us With Signs Of What's To Come

Feb 07

A Look At Yestar Healthcare Holdings' (HKG:2393) Share Price Returns

Dec 21

Do Institutions Own Yestar Healthcare Holdings Company Limited (HKG:2393) Shares?

Nov 30

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Yestar Healthcare Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:2393 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	2,714	1,078	189	228	N/A
3/31/2024	2,813	534	241	308	N/A
12/31/2023	2,913	-9	294	388	N/A
6/30/2023	2,311	-294	103	176	N/A
3/31/2023	2,558	-377	-7	42	N/A
12/31/2022	2,805	-460	-118	-92	N/A
9/30/2022	4,434	-633	93	122	N/A
6/30/2022	4,574	-274	303	336	N/A
3/31/2022	4,752	-135	484	525	N/A
12/31/2021	4,931	3	665	715	N/A
9/30/2021	4,879	83	599	671	N/A
6/30/2021	4,827	162	533	628	N/A
3/31/2021	4,467	-214	562	649	N/A
12/31/2020	4,107	-590	591	671	N/A
9/30/2020	4,163	-585	589	656	N/A
6/30/2020	4,218	-580	588	640	N/A
3/31/2020	4,561	-188	489	536	N/A
12/31/2019	4,903	203	390	432	N/A
9/30/2019	4,798	239	345	387	N/A
6/30/2019	4,692	275	300	341	N/A
3/31/2019	4,569	264	225	264	N/A
12/31/2018	4,447	252	150	187	N/A
9/30/2018	4,327	257	146	171	N/A
6/30/2018	4,206	261	143	156	N/A
3/31/2018	4,067	256	N/A	188	N/A
12/31/2017	3,927	250	N/A	221	N/A
9/30/2017	3,637	226	N/A	243	N/A
6/30/2017	3,348	202	N/A	266	N/A
3/31/2017	3,185	201	N/A	281	N/A
12/31/2016	3,022	201	N/A	296	N/A
9/30/2016	2,957	207	N/A	264	N/A
6/30/2016	2,892	213	N/A	232	N/A
3/31/2016	2,673	188	N/A	199	N/A
12/31/2015	2,455	163	N/A	165	N/A
9/30/2015	2,146	141	N/A	101	N/A
6/30/2015	1,837	119	N/A	38	N/A
3/31/2015	1,684	110	N/A	75	N/A
12/31/2014	1,531	101	N/A	113	N/A
9/30/2014	1,442	87	N/A	81	N/A
6/30/2014	1,352	74	N/A	49	N/A
3/31/2014	1,263	69	N/A	42	N/A
12/31/2013	1,173	65	N/A	36	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 2393's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 2393's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 2393's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 2393's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 2393's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 2393's Return on Equity is forecast to be high in 3 years time

Yestar Healthcare Holdings Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Yestar Healthcare Holdings Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Yestar Healthcare Holdings Company Limited Provides Earnings Guidance for the Six Months Ended 30 June 2021

Analysts lower EPS estimates to -CN¥0.0047

Recent updates

Yestar Healthcare Holdings' (HKG:2393) Attractive Earnings Are Not All Good News For Shareholders

First half 2024 earnings released: EPS: CN¥0.005 (vs CN¥0.002 in 1H 2023)

New major risk - Share price stability

Yestar Healthcare Holdings Company Limited to Report First Half, 2024 Results on Aug 29, 2024

New minor risk - Financial data availability

Yestar Healthcare Holdings Company Limited, Annual General Meeting, May 31, 2024

Full year 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.43 loss in FY 2022)

Yestar Healthcare Holdings Company Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Now 30% undervalued after recent price drop

Less than half of directors are independent

Yestar Healthcare Holdings Company Limited to Report First Half, 2023 Results on Aug 25, 2023

Yestar Healthcare Holdings Company Limited Announces Board and Committee Changes

Yestar Healthcare Holdings Company Limited Announces due to Redeem 5% of the Original Principal Amount of the New Senior Notes by 30 December 2022

Yestar Healthcare Holdings (HKG:2393) Seems To Be Using A Lot Of Debt

Now 32% undervalued after recent price drop

Less than half of directors are independent

These Return Metrics Don't Make Yestar Healthcare Holdings (HKG:2393) Look Too Strong

Now 24% undervalued after recent price drop

Is Yestar Healthcare Holdings (HKG:2393) Using Too Much Debt?

One Yestar Healthcare Holdings Company Limited (HKG:2393) Analyst Has Been Cutting Their Forecasts

Yestar Healthcare Holdings Company Limited Announces Redesignation of Hartono James from Executive Director to Non-Executive Director

First half 2022 earnings released: CN¥0.071 loss per share (vs CN¥0.048 profit in 1H 2021)

Yestar Healthcare Holdings Company Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

First half 2021 earnings released: EPS CN¥0.048 (vs CN¥0.27 loss in 1H 2020)

First half 2021 earnings released: EPS CN¥0.048 (vs CN¥0.27 loss in 1H 2020)

Yestar Healthcare Holdings Company Limited Provides Earnings Guidance for the Six Months Ended 30 June 2021

Returns On Capital At Yestar Healthcare Holdings (HKG:2393) Have Hit The Brakes

Independent Non-Executive Director Tirtamarta Karsono has left the company

Full year 2020 earnings released: CN¥0.25 loss per share (vs CN¥0.085 profit in FY 2019)

These 4 Measures Indicate That Yestar Healthcare Holdings (HKG:2393) Is Using Debt Extensively

Full year 2020 earnings released: CN¥0.25 loss per share (vs CN¥0.085 profit in FY 2019)

Yestar Healthcare Holdings Company Limited to Report Fiscal Year 2020 Results on Mar 29, 2021

What Kind Of Investors Own Most Of Yestar Healthcare Holdings Company Limited (HKG:2393)?

The Returns At Yestar Healthcare Holdings (HKG:2393) Provide Us With Signs Of What's To Come

New 90-day low: HK$1.10

New 90-day low: HK$1.18

A Look At Yestar Healthcare Holdings' (HKG:2393) Share Price Returns

New 90-day low: HK$1.23

Do Institutions Own Yestar Healthcare Holdings Company Limited (HKG:2393) Shares?

Analysts lower EPS estimates to -CN¥0.0047

Yestar Healthcare Holdings Company Limited Announces Board Changes

First half earnings released

Earnings released

Yestar Healthcare Holdings Company Limited to Report First Half, 2020 Results on Aug 24, 2020

New 90-day high - HK$1.30

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies